Through analysis of circulating inflammatory markers and IL-6 promoter genotyping, our cohort was notable for highly inflammatory features, including higher levels of baseline circulating CRP than previously published cohorts of metastatic BC patients25 and a 60% frequency of high-risk IL-6 genotypes. Here, IL6 is linked to breast cancer.